Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Kala Pharmaceuticals diskutieren

Kala Pharmaceuticals Inc.

WKN: A3DWPS / Symbol: KALA / Name: Kala Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

?
-2,10 %

Einschätzung Buy
Rendite (%) -44,50 %
Kursziel 18,53
Veränderung
Endet am 27.03.24

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -57,52 %
Kursziel 21,91
Veränderung
Endet am 11.08.24

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $24.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) 26,60 %
Kursziel 20,23
Veränderung
Endet am 17.11.24

KALA BIO, Inc. (NASDAQ: KALA) had its price target lowered by analysts at HC Wainwright from $24.00 to $22.00. They now have a "buy" rating on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -32,11 %
Kursziel 13,96
Veränderung
Endet am 01.04.25

KALA BIO, Inc. (NASDAQ: KALA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -38,22 %
Kursziel 19,50
Veränderung
Endet am 02.04.25

KALA BIO, Inc. (NASDAQ: KALA) had its price target lowered by analysts at HC Wainwright from $22.00 to $21.00. They now have a "buy" rating on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -45,78 %
Kursziel 16,55
Veränderung
Endet am 17.05.25

KALA BIO, Inc. (NASDAQ: KALA) had its price target lowered by analysts at HC Wainwright from $21.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) 28,32 %
Kursziel 13,55
Veränderung
Endet am 19.08.25

KALA BIO, Inc. (NASDAQ: KALA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -90,91 %
Kursziel 14,25
Veränderung
Endet am 15.11.25

KALA BIO, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -93,60 %
Kursziel 14,43
Veränderung
Endet am 13.02.26

KALA BIO, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -85,64 %
Kursziel 13,55
Veränderung
Endet am 04.04.26

KALA BIO, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -86,29 %
Kursziel 10,60
Veränderung
Endet am 23.05.26

KALA BIO, Inc. (NASDAQ: KALA) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -84,67 %
Kursziel 13,19
Veränderung
Endet am 02.06.26

KALA BIO, Inc. (NASDAQ: KALA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $15.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -90,87 %
Kursziel 10,28
Veränderung
Endet am 11.07.26

KALA BIO, Inc. (NASDAQ: KALA) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $12.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

KALA BIO, Inc. (NASDAQ: KALA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -96,19 %
Kursziel 25,62
Veränderung
Endet am 08.09.26

KALA BIO (NASDAQ:KALA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $30.00 price target on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -96,52 %
Kursziel 28,21
Veränderung
Endet am 11.09.26

KALA BIO (NASDAQ:KALA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $15.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for KALA provided by MarketBeat

Einschätzung Buy
Rendite (%) -97,11 %
Kursziel 29,52
Veränderung
Endet am 17.09.26

KALA BIO (NASDAQ:KALA) had its price target raised by analysts at HC Wainwright from $12.00 to $35.00. They now have a "buy" rating on the stock.
Ratings data for KALA provided by MarketBeat